IS5718A - Use of alpha1β1 integrin receptor antagonists and TGF-β1 inhibitors in the treatment of kidney disease - Google Patents

Use of alpha1β1 integrin receptor antagonists and TGF-β1 inhibitors in the treatment of kidney disease

Info

Publication number
IS5718A
IS5718A IS5718A IS5718A IS5718A IS 5718 A IS5718 A IS 5718A IS 5718 A IS5718 A IS 5718A IS 5718 A IS5718 A IS 5718A IS 5718 A IS5718 A IS 5718A
Authority
IS
Iceland
Prior art keywords
alpha1β1
tgf
inhibitors
treatment
receptor antagonists
Prior art date
Application number
IS5718A
Other languages
Icelandic (is)
Inventor
Cosgrove Dominic
Original Assignee
Boys Town National Research Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/292,534 external-priority patent/US6492325B1/en
Priority claimed from PCT/US1999/011073 external-priority patent/WO1999061040A2/en
Application filed by Boys Town National Research Hospital filed Critical Boys Town National Research Hospital
Publication of IS5718A publication Critical patent/IS5718A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS5718A 1998-05-22 2000-11-21 Use of alpha1β1 integrin receptor antagonists and TGF-β1 inhibitors in the treatment of kidney disease IS5718A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8658798P 1998-05-22 1998-05-22
US8876698A 1998-06-02 1998-06-02
US15048598A 1998-09-09 1998-09-09
US09/292,534 US6492325B1 (en) 1998-05-22 1999-04-15 Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
PCT/US1999/011073 WO1999061040A2 (en) 1998-05-22 1999-05-19 USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE

Publications (1)

Publication Number Publication Date
IS5718A true IS5718A (en) 2000-11-21

Family

ID=27492055

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5718A IS5718A (en) 1998-05-22 2000-11-21 Use of alpha1β1 integrin receptor antagonists and TGF-β1 inhibitors in the treatment of kidney disease

Country Status (2)

Country Link
IL (2) IL139687A0 (en)
IS (1) IS5718A (en)

Also Published As

Publication number Publication date
IL139687A (en) 2007-12-03
IL139687A0 (en) 2002-02-10

Similar Documents

Publication Publication Date Title
IS6411A (en) Kaspasa inhibits and their use
DK1354888T3 (en) Glucopyranosyloxypyrazole derivatives and their use in drugs
EE200100480A (en) Xenon for use in the treatment of nerve poisoning
NO20014560D0 (en) Quinasolines and their therapeutic use
EE200100524A (en) Use of CYP2D6 inhibitors in combination therapy
DK1122244T3 (en) Uracil compounds and their use
IS5696A (en) Antibodies against CD23, their derivatives and their therapeutic use
NO20020343D0 (en) Caspase inhibitors and their use
IS7040A (en) 5-HT receptors and their use
NO20001754D0 (en) Prostaglandin agonists and their use in the treatment of bone disorders
EE200100659A (en) Diaminothiazoles and their use for the inhibition of protein kinases
NO20021379D0 (en) Benzodiazepine derivatives, preparation and use thereof
HK1054225A1 (en) Mch antagonists and their use in the treatment of obesity
ID22565A (en) USE OF NANODISPERION IN FINAL DRUG FORMULATION
DK1212317T3 (en) Indole derivatives and their use in the treatment of osteoporosis among other uses
HUP0202048A3 (en) Use of alpha1betha1 integrin receptor inhibitors and tgf-betha1 inhibitors in the treatment of kidney disease
NO20004274D0 (en) Protease-activated receptor 4 and its use
DE69903961D1 (en) MUSCARINAGONISTS AND ANTAGONISTS
NO20004355D0 (en) Retarding systems and their use in oil well cementing
IS6966A (en) Cyano-linked dihydropyrimidine compounds and their use in the treatment of diseases
IS6967A (en) New cyano-linked dihydropyrimidine compounds and their use in the treatment of diseases
DK1106607T3 (en) Uracil compounds and their use
NO20030156D0 (en) Pharmaceutical compositions and methods for their use
ATE317386T1 (en) DIHYDROINDOLE AND TETRAHYDROCINOLINE DERIVATIVES
PT1448566E (en) CHEMICOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF